LAMIVUDINE (Major Pharmaceuticals)
Welcome to the PulseAid listing for the LAMIVUDINE drug offered from Major Pharmaceuticals. This Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Major Pharmaceuticals |
| NON-PROPRIETARY NAME: | lamivudine |
| SUBSTANCE NAME: | LAMIVUDINE |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |
| ROUTE: | ORAL |
| DOSAGE FORM: | TABLET, FILM COATED |
| MARKETING CATEGORY NAME: | ANDA |
| START MARKETING DATE: | 2011-12-02 |
| END MARKETING DATE: | 0000-00-00 |
LAMIVUDINE HUMAN PRESCRIPTION DRUG Details:
| Item Description | LAMIVUDINE from Major Pharmaceuticals |
| LABELER NAME: | Major Pharmaceuticals |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 150(mg/1) |
| START MARKETING DATE: | 2011-12-02 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0904-6583_6fd4d6b9-65ea-4988-8d6f-dd220ec5052d |
| PRODUCT NDC: | 0904-6583 |
| APPLICATION NUMBER: | ANDA091606 |
Other LAMIVUDINE Pharmaceutical Manufacturers / Labelers:
